Note 9 - Segment Information and Disaggregated Revenue

9 Months Ended

Mar. 31, 2024

Notes to Financial Statements

Segment Reporting Disclosure [Text Block]

Note 9. Segment Information and Disaggregated Revenue

The basis for presenting segment results generally is consistent with overall Company reporting. The Company reports information about its operating segments in accordance with GAAP which establishes standards for reporting information about a company’s operating segments.

The Company has divided its operations into two reportable segments as follows: Contract Manufacturing, and Other Nutraceutical Businesses. International sales, concentrated primarily in Europe, for the three months ended March 31, 2024 and 2023 were $1,980 and $2,188, respectively and for the nine months ended March 31, 2024 and 2023 were $5,245 and $6,576, respectively.

Financial information relating to the three months ended March 31, 2024 and 2023 operations by business segment and disaggregated revenues was as follows:

		Sales, Net						Segment
		U.S.		International				Gross					Capital
		Customers		Customers		Total		Profit (loss)			Depreciation		Expenditures
Contract Manufacturing	2024	$	10,770	$	2,980	$	12,750	$	1,250		$	77	$	345
	2023		10,417		2,180		12,597		978			86		16
Other Nutraceutical Businesses	2024		397		-		397		(2	)		-		-
	2023		493		8		501		30			-		-
Total Company	2024		11,167		1,980		13,147		1,248			77		345
	2023		10,910		2,188		13,098		1,008			86		16

Financial information relating to the nine months ended March 31, 2024 and 2023 operations by business segment and disaggregated revenues was as follows:

		Sales, Net						Segment
		U.S.		International				Gross				Capital
		Customers		Customers		Total		Profit		Depreciation		Expenditures
Contract Manufacturing	2024	$	31,022	$	5,218	$	36,240	$	2,563	$	231	$	404
	2023		29,272		6,568		35,840		2,745		265		98
Other Nutraceutical Businesses	2024		1,304		27		1,331		37		1		3
	2023		1,830		8		1,838		330		2		-
Total Company	2024		32,326		5,245		37,571		2,600		232		407
	2023		31,102		6,576		37,678		3,075		267		98

	Total Assets as of
	March 31,		June 30,
	2024		2023
Contract Manufacturing	$	21,097	$	19,507
Other Nutraceutical Businesses		5,845		5,924
Total Company	$	26,942	$	25,431